Evaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C
Frontiers in Toxicology · 25.05.2026 · 8
DOI: 10.3389/ftox.2026.1783444 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Toxicology, online erschienen am 25.05.2026. Verfasst von Yu-Hai Ma und 9 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Lanatoside C (Lan C), a cardiac glycoside, has demonstrated potent anti-cholangiocarcinoma activity. However, its potential cardiotoxicity at therapeutic doses remains poorly understood. This study aimed to systematically evaluate the cardiotoxicity of Lan C at cellular and organ levels and to elucidate its underlying molecular mechanisms.
Methods
Human AC16 cardiomyocytes (ATCC® CRL-3568™) were employed for in vitro studies, with untreated cells included as negative controls. Cytotoxic effects at anti-cholangiocarcinoma-relevant concentrations (50–200 nM) were evaluated using a combination of cell viability assays, transmission electron microscopy, flow cytometry for apoptosis and reactive oxygen species (ROS) detection, JC-1 staining to assess mitochondrial membrane potential, lactate dehydrogenase (LDH) release assays, and Western blot analysis of apoptotic proteins. Male BALB/c mice were administered either vehicle (PBS) or Lan C (80 mg/kg/day) by oral gavage for 28 consecutive days. Cardiac function was assessed by echocardiography, and myocardial architecture was examined through histopathological analysis.
Results
Lan C showed a dose-dependent inhibitory effect in vitro on AC16 cell viability and induced apoptosis. This process involved decreased mitochondrial membrane potential, increased reactive oxygen species (ROS), downregulation of the anti-apoptotic protein Bcl-2, and upregulation of cytochrome C, Cleaved Caspase-9, and Cleaved Caspase-3, indicating activation of the mitochondrial-dependent apoptotic pathway. In vivo , high-dose Lan C significantly impaired left ventricular systolic function, as indicated by reductions in LVEF and LVFS, and induced myocardial structural alterations.
Conclusion
Lan C exhibits measurable but relatively low cardiotoxicity at concentrations effective against cholangiocarcinoma, with cardiac effects may be manageable at therapeutic doses. These findings support Lan C as a promising anti-tumor candidate with controllable cardiotoxicity under optimized dosing and clinical monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The First Clinical Medical College, Lanzhou University, Lanzhou, Gansu, China.
- Department of Emergency, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
- Gansu Province Key Laboratory Biotherapy and Regenerative Medicine, Lanzhou, China.
- Department of General Surgery, The First Hospital of Lanzhou University, Lanzhou, Gansu, China.
- State Key Laboratory of Applied Organic Chemistry, College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, China.
Zitieren
APA
Ma, Y. H., Huang, C. F., Ma, H. D., Zhao, J. Y., Wang, W. A., Dong, Z. H., Shao, Y., Gao, L., Chen, J. J., & Meng, W. B. (2026). Evaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C. Frontiers in Toxicology, 8. https://doi.org/10.3389/ftox.2026.1783444
Vancouver
Ma YH, Huang CF, Ma HD, Zhao JY, Wang WA, Dong ZH, et al. Evaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C. Frontiers in Toxicology. 2026;8. doi:10.3389/ftox.2026.1783444
BibTeX
@article{Ma2026,
author = {Ma, Yu-Hai and Huang, Chong-Fei and Ma, Hai-Dong and Zhao, Jin-Yu and Wang, Wen-An and Dong, Zi-He and Shao, Yi and Gao, Long and Chen, Jian-Jun and Meng, Wen-Bo},
title = {Evaluation and investigation of the cardiotoxicity of the potential anti-cholangiocarcinoma drug lanatoside C},
journal = {Frontiers in Toxicology},
year = {2026},
volume = {8},
doi = {10.3389/ftox.2026.1783444}
}
EUVIMED